Zentek has announced its intention to complete a non-brokered private placement of up to CAD$3 million (around USD$2,180,000). Gross proceeds of the offering will be used for working capital and general corporate purposes.
In May 2024, Zentek received a patent by the Canadian Intellectual Property Office, titled: Graphene Oxide-Cationic Silver (GO-Ag+) Nanocomposites and Their Use as a Broad-Spectrum Antimicrobial Agent. In December 2023, Zentek announced the launch of Triera Biosciences as its wholly owned subsidiary for its aptamer platform technology. Then, in May 2024, Zentek and Triera Biosciences announced achieving positive results against Avian Influenza (H5N1) using their Multivalent Aptamer Technology.
Posted: Jul 23,2024 by Roni Peleg
